Compare Johnson & Johnson (JNJ) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Williams-Sonoma, Inc. — how do they compare? Johnson & Johnson trades at $249.2 (market cap $598.96B), while Williams-Sonoma, Inc. trades at $221.6 (market cap $26.30B). The key difference: Johnson & Johnson is far larger — about 22.8× Williams-Sonoma, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | WSM | |
|---|---|---|
Market Cap | $598.96B | $26.30B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $240.06 |
52-Week Low | $164.36 | $168.64 |
Enterprise Value | $631.90B | $27.14B |
Dividend Yield | 2.15% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Williams-Sonoma (WSM) trades at $223.34, down 2.22% today, with a bullish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with 13.81% net margins and 54.01% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent earnings beats and consistent dividend payments highlight operational strength amid competitive retail pressures.
WSM presents a mixed outlook with solid fundamentals but faces revenue headwinds and high valuation multiples. Analyst consensus is cautious with 60.72% hold ratings and a $215.22 price target below current levels. Key risks include consumer discretionary spending volatility and execution challenges in maintaining premium positioning against competitors like RH.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
